Navigation Links
Gene Network Sciences Announces Drug Development Collaboration with Biogen Idec
Date:10/1/2008

CAMBRIDGE, Mass., Oct. 1 /PRNewswire/ -- Gene Network Sciences, Inc. (GNS) today announced that it has entered into an agreement with Biogen Idec under which GNS will use its proprietary REFS(TM) software platform to process clinical data provided by Biogen Idec to identify targets and biomarkers in inflammation. A forward simulation model generated directly from the Biogen Idec data will be licensed to Biogen Idec at the conclusion of this project. Financial terms of the agreement were not disclosed.

GNS employs massively parallel supercomputers to probe vast amounts of raw human biological data to discover new insights into the biological causes of human disease, and new opportunities for diagnosis and treatment. Under this agreement, GNS will use its REFS(TM) (Reverse Engineering/Forward Simulation) platform to transform genetic, genomic, and clinical data provided by Biogen Idec to generate and score billions of hypotheses to discover new drug targets and biomarkers rapidly.

"Our proprietary technology is capable of taking raw 'omic' data and running billions of calculations in a short period of time to find potential biomarkers and promising drug targets that could lead to more effective patient treatments," said Colin Hill, CEO of GNS. "It is the value and speed of our REFS(TM) technology and the potential it offers to the Biogen Idec drug development program that forged our partnership."

About REFS(TM)

Reverse Engineering/Forward Simulation (REFS(TM)) is a technology that systematically turns multiple layers of biologically relevant data into an unprecedented view of human biology and disease as a "whole." REFS(TM) begins with raw biological data (genetic, genomic, epigenetic, proteomic, metabolomic and environmental) and rapidly performs billions upon billions of calculations to determine how the molecules interact with one another in the complete system (Reverse Engineering). These computer-assembled models are then queried rapidly through billions of in silico experiments (Forward Simulation) to discover the highest-impact molecular targets for the disease being studied and the corresponding efficacy and toxicity markers related to specific drug treatments. These findings are then tested in both the laboratory and the clinic, enabling a faster, more focused and more effective drug discovery and development process.

About Gene Network Sciences

Founded in 2000, Gene Network Sciences (http://www.gnsbiotech.com/) is a leader in biosimulation with its ability to derive molecular mechanisms of drugs and diseases directly from molecular profiling and clinical data without any a priori knowledge. Headquartered in Cambridge, Massachusetts, GNS uses its REFS(TM) (reverse engineering and forward simulation) technology in pharmaceutical and clinical settings to rapidly turn complex and heterogeneous data sets into cell and organ-level computer models of disease biology, drug efficacy and drug safety. These models simulate mechanisms of disease and the clinical performance of drug candidates. By discovering how and why specific drug candidates impact human biology, GNS technology enables the rapid development of breakthrough drug and diagnostic products.

For more Information, please contact:

Lynn Blenkhorn Thomas Neyarapally

Feinstein Kean Healthcare Gene Network Sciences, Inc.

508-851-0930 617-494-0492

Lynn.blenkhorn@fkhealth.com tneyarapally@gnsbiotech.com


'/>"/>
SOURCE Gene Network Sciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Access Innovations Provides Support Services for Agis Network
2. Womens World Banking Welcomes New Network Member From Tunisia
3. Internet TV Network for Personal Trainers is Launched
4. Quality Innovators to Network in Atlanta Sept. 19-21: Learn from Those Who Got It Right
5. Guardians Dental Network Experiences Double-Digit Growth
6. Chronic infection persists by targeting stromal cell network in lymphoid organs
7. The American Pain Foundation (APF) and The HealthCentral Network Collaborate to Develop Enhanced Internet Resources for People with Pain
8. Blue Care Network of Michigan Earns National Leadership Award for Chronic Disease Management
9. AT&T Offers Network Industry-First RFID Solution for Health Care Organizations
10. AT&T Establishes New Network Services for Leading Medical Liability Insurer
11. Portico Systems to Share Provider Network Management Best Practices at Institute for International Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2016)... ... May 26, 2016 , ... American ... chief medical officer of Blue Horizon International (BHI), Brian Mehling, M.D., spoke at ... held during May 5-6, 2016 in Chicago, IL, USA. Dr. Mehling’s presentation was ...
(Date:5/26/2016)... , ... May 26, 2016 , ... ... and products recently hosted the first PowerWave Instructor Certification Course in Stoughton, Massachusetts. ... a group of fitness professional through the 8 hour interactive course to qualify ...
(Date:5/26/2016)... ... May 26, 2016 , ... On May 23rd during ... Water Life Science® and international water advocate, was honored by Ashram, Inc. as the ... ancient Egypt who knelt on the banks of the Nile to fill their red ...
(Date:5/26/2016)... ... May 26, 2016 , ... Workrite ... sales leadership and to further develop their rapidly expanding portfolio of customer and ... with a concentration in Marketing and an M.B.A. with concentration in management from ...
(Date:5/26/2016)... ... , ... May 2016 – Lips may be a central feature on our ... numbers of clients now ask about lip plumping and primping techniques and want tips ... Advanced Dermatology P.C. , The trend is a national one, with 2.4 ...
Breaking Medicine News(10 mins):
(Date:5/25/2016)... CHESTERFIELD, Va. , May 25, 2016 /PRNewswire/ ... next-generation sequencing test for wounds and infections. This ... ALL parasites, and select viruses. The test requires ... area. David G. Bostwick ... molecular testing to facilitate wound healing: "We are ...
(Date:5/25/2016)... 2016 ReportsnReports.com adds "Chronic ... that provides an overview on therapeutic pipeline of ... stages, therapeutics assessment by drug target, mechanism of ... type, along with latest updates, and featured news ... involved in the therapeutic development for Chronic Cough ...
(Date:5/24/2016)...   , Study met ... bowel cleansing and superiority in , ... of the ascending colon   ... Norgine B.V. today announced new positive data from the phase ... preparation) versus standard 2 litre PEG with ascorbate. The study met ...
Breaking Medicine Technology: